IMF Videos Search Content For Healthcare Professional (70) Healthcare Provider (70) Series - Any - About the IMF (2) ASCO/EHA (70) ASH (102) Ask Dr. Durie (150) Black Swan Research Initiative (7) Community Workshops (5) Emerging Therapies (18) Facebook Live (21) Health Equity (14) IMF History (3) IMWG (12) Inspirational (15) Living Well with Myeloma (33) Myeloma in a Minute (20) Myeloma Made Simple (15) Myeloma University (12) NLB Webcasts (1) Patient & Family Webinar (11) Q&A (21) Recent News and Developments (5) Treatments (3) Trending Searches in Myeloma (4) Topics Clinical Trials (49) Financial Considerations (1) Frontline Therapy (16) Health Equity (2) Lab & Imaging Tests (1) Mental & Emotional Health (1) Myeloma in the News (1) Public Policy & Advocacy (1) Recorded Webinars (2) Relapse/Refractory Myeloma (31) Research Updates (51) Symptom Management (4) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (16) High-Risk Myeloma (14) High-risk Smoldering Myeloma (9) Late Relapse (4–6 Lines of Therapy) (29) MGUS (5) Newly Diagnosed (Pre-Treatment or First Treatment) (20) Smoldering Myeloma (7) Types of Therapy Immunomodulatory drugs (IMiDs) (22) Immunotherapies (CAR T; BiTE, etc.) (30) Monoclonal antibodies (20) Proteasome inhibitors (20) Stem cell transplant (10) Steroids (17) Supportive Care (8) Year Published 2026 (1) 2025 (14) 2024 (17) 2023 (17) 2022 (1) 2021 (3) 2020 (3) 2019 (2) 2018 (2) 2017 (5) 2015 (5) Trusted Voices Dr. Joseph Mikhael (2) Dr. María-Victoria Mateos (1) Dr. S. Vincent Rajkumar (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance Elranatamab: Extended Follow-up & Biweekly Admin for RRMM | MagnetisMM-3 Study June 13, 2023 ASCO/EHA African Americans with SMM may have a lower risk of progression compared to White patients June 24, 2022 ASCO/EHA Updated Interim Analysis of the GMMG-CONCEPT Trial Investigating Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone (Isa-KRd) in Frontline Treatment of High-Risk Multiple Myeloma June 14, 2021 ASCO/EHA Depth of response and minimal residual disease status in ultra high-risk multiple myeloma and plasma cell leukemia treated with DARA-CVRd: Results of the UK optimum/MUKnine trial June 9, 2021 ASCO/EHA Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma according to prior lines of treatment and refractory status: IKEMA subgroup analysis June 8, 2021 ASCO/EHA Isatuximab Plus Carfilzomib and Dexamethasone (ISA-Kd) Vs Kd In RRMM (IKEMA): Interim Analysis of A Phase III, Randomized, Open-Label Study June 16, 2020 ASCO/EHA Analysis of treatment efficacy in the GEM-CESAR trial for high-risk smoldering multiple myeloma patients June 11, 2020 ASCO/EHA Clinical implications of loss of minimal residual disease (MRD) negativity in multiple myeloma June 7, 2020 ASCO/EHA Outcomes of patients with t(11;14) multiple myeloma: An international myeloma working group (IMWG) multicenter study June 4, 2019 ASCO/EHA Updated risk stratification model for smoldering multiple myeloma (SMM) incorporating the revised IMWG diagnostic criteria June 2, 2019 ASCO/EHA Value and cost of multiple myeloma therapy June 4, 2018 ASCO/EHA Pomalidomide, bortezomib, and low‐dose dexamethasone vs bortezomib and low-dose dex in lenalidomide-exposed patients with relapsed or refractory MM June 4, 2018 ASCO/EHA Load More
